|
Clustering & Synthetic data generating processes (SDPDs)
|
|
0
|
13
|
April 15, 2026
|
|
How can I communicate hazard ratios from log-transformed biomarkers in a clinically interpretable way?
|
|
4
|
94
|
April 3, 2026
|
|
Statin-related side effects: the recent Lancet publication is biased toward false-negatives
|
|
19
|
478
|
February 19, 2026
|
|
Randomized non-comparative trials: an oxymoron?
|
|
73
|
4498
|
December 15, 2025
|
|
A High-Fiber Plant-Based Diet in Myeloma Precursor Disorders – Results from the 2 NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
|
|
2
|
97
|
December 11, 2025
|
|
Introduction to Forensic Metascience: Techniques to check the credibility of scientific reports
|
|
0
|
95
|
December 7, 2025
|
|
NEJM Trial - proportional hazard assumption
|
|
12
|
392
|
December 1, 2025
|
|
Omission of *absolute* risk reduction from NEJM Editorial on PSA testing
|
|
14
|
452
|
November 27, 2025
|
|
Rarity Roulette: A simulator for estimating hypothetical outcomes spreads for mass screenings
|
|
2
|
95
|
November 20, 2025
|
|
Individual response
|
|
266
|
49096
|
November 17, 2025
|
|
Feedback on BayeScores: A Bayesian AFT Mixture Cure Model for Quantifying Clinical Benefit
|
|
3
|
151
|
November 11, 2025
|
|
The rooster's crowing
|
|
0
|
122
|
October 20, 2025
|
|
When and why (not) to worry about the PO assumption
|
|
4
|
668
|
October 9, 2025
|
|
Fine-Gray vs Cause-Specific Cox Regression
|
|
0
|
150
|
September 11, 2025
|
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
32
|
4257
|
August 12, 2025
|
|
Causal inferences from RCTs- could “toy” clinical examples promote understanding?
|
|
17
|
2399
|
August 4, 2025
|
|
Accounting for period effect in crossover studies with washout
|
|
0
|
73
|
July 2, 2025
|
|
Why the Non-Reproducibility of Acute Care RCT? The CAP studies
|
|
6
|
205
|
May 8, 2025
|
|
Biobanks, data dredging and science-by-press-release
|
|
4
|
131
|
April 30, 2025
|
|
Lest we forget: “Epidemiology faces its limits”- 30 years later…
|
|
19
|
1367
|
April 3, 2025
|
|
Marginalizing predictions over categories of continuous predictors for lay audience presentations
|
|
5
|
472
|
January 28, 2025
|
|
Summary table of different Cox PHM models to compare them
|
|
7
|
1035
|
December 23, 2024
|
|
Interrupted Time Series, estimates before and after jump
|
|
2
|
755
|
November 23, 2024
|
|
Non Inferiority vs Non significant
|
|
17
|
1673
|
December 19, 2024
|
|
Least damaging way to convert model predictions to scores
|
|
8
|
770
|
November 29, 2024
|
|
Advice for appropriate causal model and analysis method
|
|
13
|
2032
|
November 19, 2024
|
|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
6
|
8717
|
November 5, 2024
|
|
Interpreting the coefficient of a log transformed dependent variable
|
|
2
|
930
|
September 11, 2024
|
|
Use of percentage change in clinical trials
|
|
17
|
9644
|
July 22, 2024
|
|
Evaluating seizures in open-label studies
|
|
8
|
1322
|
July 21, 2024
|